So excited to check out RheumNow’s ACR Mid-Meeting Recap live right now with Dr. Jack Cush (@rheumnow), Dr. Arthur Kavanaugh, Dr. Michale Pillinger, and Dr. Bella Mehta! #ACR20

This single slide tries to summarise all major phase3 clinical trials in Psoriatic Arthritis 💪 Take your time. The top half looks at joint efficacy. The bottom half for skin efficacy. #ACR20 https://t.co/FXhJunXNKt

RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow + its Faculty.

EQUATOR2 52wk extension trial - Filgotinib on enthesitis in PsA pts 1️⃣Clinical resolution of enthesitis at 52wks 77% by LEI and SPARCC 2️⃣Pts who did not respond by wk 16➡️77% and 81% resolution enthesitis by LEI and SPARCC @RheumNow #ACR20 Abs#0910 https://t.co/mCe32rrAcc

Health plan claims data appears useful to classify inadequate responders in PsA and should be studied further. #ABS0898 #ACR20 @RheumNow https://t.co/jXBr54Fc6Z https://t.co/fAESyo5Uad

• Inadequate Response Among Psoriatic Arthritis Patients Prescribed Advanced Ther…

Neihulizumab, novel immune checkpoint agonistic ab that binds to human CD162 (PSGL-1), thereby preferentially inducing apoptosis in late stage activated T cells. Phase II trial shows efficacy in PsA, further trials to come. #ABS0894 #ACR20 @RheumNow https://t.co/gzf7epPyNd https://t.co/ArLlCyzLxR

• Efficacy and Safety of Neihulizumab (AbGn-168H) in Patients with Active Psoriat…

Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect of IL-17i and JAKi with PsA rated highly. This study highlights ever-growing need for precision medicine based on domain. #ABS09003 #ACR20 @RheumNow https://t.co/7qKH6aw6f0

• Changing Patterns of Use of Biologic/Targeted Synthetic DMARDs in Psoriatic Art…

BKZ tx improved BASDAI total and single question scores related to fatigue and neck, back and hip pain in pts with PsA. #ABS0906 #ACR20 @RheumNow https://t.co/GzpJfkwvL5 https://t.co/KnJAqAKlqq

• Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue …

In the search for biomarkers in PsA, interesting study showing absolute lymphocyte count is negatively correlated with cardiovascular disease risk score and red cell distribution width and increases with TNF-Inhibitor Therapy @rheumnow #ACR20 Abstr#878

Dr. J. Walsh slide on PROs in PsA research. #ACR20 ⁦@RheumNow⁩ https://t.co/v4ufUdWufB

RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by Novartis. All content chosen by @RheumNow and its Faculty.

FUTURE2 analysis of 78 TJC and 76 SJC scores in PsA pts treated with SEC demonstrated improvements in synovitis at Week 24 sustained over 5 years, irrespective of TNFi history & concomitant MTX use. #ABS0875 #ACR20#ACRbest @RheumNow https://t.co/U8B50PTWET https://t.co/fUK1JO10ox

• Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tende…

CORRONA: Majority of PsA pts who initiated an advanced therapy had mild to moderate skin involvement. Decision to change therapy w/ rheumatologist based mainly on MSK symptoms. #ABS0873 #ACR20 @RheumNow https://t.co/mOXg5B7goI https://t.co/mqddMYQ3i0

• Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arth…